sanofi_advert_Layout 1 09/02/2010 10:26 Page 5
Diagnosed with bladder cancer
*
Michael
still wants to go on that romantic
getaway
Improve his chances of disease-free survival
…with ImmuCyst
®
maintenance therapy
1,2
Maintenance provides superior protection
1,2
BCG maintenance provides better outcomes
(Median follow-up >7 yrs)
than chemotherapy
6 week Induction+
induction only maintenance**
Significantly
OR
Proven to
superior in reducing reduce the risk of
OR
Tumour reduced
recurrence
0.42
progression,
recurrence
52
%
by half
25
%
compared to unlike
(p<0.0001)
chemotherapy
3†
chemotherapy
4,6‡
0.63
Median
more than
p<0.001 p=0.00004
recurrence-free
3.0 yrs
doubled
6.4 yrs
survival
(p<0.0001)
*Non-muscle invasive bladder cancer (stage Ta, T1 or CIS)
**3 week maintenance schedule
†Analysis of 11 comparative trials of BCG and mitomycin C in patients with Ta or T1 tumours; n=2,749, overall median follow-up 26 months. Based on subset of 6 trials with BCG maintenance, n=1,552
(several different strains of BCG), odds ratio 0.42, 95% CI 0.30-0.58.
‡Analysis of 24 trials with progression information on patients with stage Ta, T1 or CIS; n=4,863, median follow-up 2.5 years, maximum 15 years. Based on subset of 20 trials with BCG maintenance, n=2,065
(several different strains of BCG), odds ratio 0.63, 95% CI 0.51-0.79.
For more information on ImmuCyst
®
, please visit www.ImmuCyst.com
ImmuCyst
®
is indicated for:
5
• treatment of primary or recurrent CIS, prophylaxis of recurrent CIS • prophylaxis following TUR of primary or
recurrent stage Ta and/or T1 papillary tumours • any combination of the above, regardless of antecedent intravesical treatment
BCG Connaught Strain
Strength from within
ImmuCyst®is a registered trademark of sanofi pasteur.
©
2009 Sanofi Pasteur Limited
1. Lamm DL. Preventing progression and improving survival with BCG maintenance. Eur Urol 2000;37(supp 1):9-15. 2. Lamm DL, et al. Maintenance bacillus Calmette-Guérin immunotherapy
for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group study. J Urol 2000 April;163(4):1124-1129.
3. Böhle A, et al. Intravesical bacillus Calmette-Guérin versus Mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol
2003 Jan;169(1):90-95. 4. Sylvester RJ, et al. Intravesical bacillus Calmette-Guérin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis
of the published results of randomized clinical trials. Journal of Urology 2002 Nov;168(5):1964-1970. 5. ImmuCyst® Product Monograph, November 2008. 6.
Pawinski A, et al. A combined analysis of European Organization for Research and Treatment of Cancer, and Medical Research Council
randomized clinical trials for the prophylactic treatment of TaT1 bladder cancer.
J Urol 1996;156(6):1934-1941.
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100